Lipid storage myopathies are a rare but serious cause of muscle weakness characterised by the accumulation of abnormal amounts of neutral fat in type 1 fibres. A case is reported in which the patient presented with weakness of the proximal limb muscles and greatly increased activities of creatine kinase and lactate dehydrogenase. After two years lipid myopathy was diagnosed when electron microscopy confirmed the presence of large numbers of lipid particles within muscle fibres. Twelve years after the initial presentation propranolol (40 mg thrice daily) was started. Strength gradually improved and enzyme activities returned to normal.
Introduction
Lipid storage myopathies, a group of disorders characterised by the accumulation of neutral fat in type 1 muscle fibres, are a rare but sometimes fatal cause of severe muscle weakness.'-3 Two biochemical defects leading to the disorder have been identified-namely, carnitine deficiency4 and deficiency of the enzyme carnitine palmityl transferase.5 Both these defects affect the ability of the muscle cell to transport long-chain fatty acids across the mitochondrial membrane. Other lipid storage myopathies have been described in which the enzymatic defect is unknown. 6 Dietary modification to reduce intake of long-chain fatty acids, oral carnitine supplementation, and corticosteroids have all been reported as producing improvement in 
Discussion
This patient showed a combination of proximal muscle weakness and a great excess of triglyceride in type 1 muscle fibres. He did not develop muscle pain on exercise, his plasma lipid concentrations were normal, and he could produce ketones on fasting. This syndrome accords with previous descriptions of the clinical features of the lipid storage myopathy associated with carnitine deficiency.8 12 Spontaneous remissions have been reported in this condition,'2 but in view of our patient's 12-year history of continuous profound muscle weakness with persistently raised activities of creatine kinase and lactate dehydrogenase it seems unlikely that treatment with propranolol coincided with a spontaneous remission in his case.
The mode of action of propranolol, however, is a mystery. Fasting plasma concentrations of non-esterified fatty acids, triglycerides, and cholesterol were not appreciably altered by the drug in this patient. Its effect, therefore, is unlikely to reside in altering the amount of circulating long-chain fatty acids available for muscle metabolism. Changes in numbers of mitochondria in rabbit ventricuiar myocardium after exposuie to proprano1ol have been reported,1' and possibly the action of the drug is directly on the muscle mitochondria and has nothing to do with beta-adrenergic blockade. Vitamin A toxicity can contribute to hypercalcaemia in patients undergoing haemodialysis, probably by an Introduction Serum vitamin A concentrations are raised in chronic renal failure,'-3 but little is known about the potential toxic effects of the excess vitamin A. In tissue culture vitamin A has been shown to have an osteolytic action,4 5 and in rats toxic quantities of vitamin A produced an intensification of resorption processes.6 7 Hypercalcaemia and skeletal lesions have also been described in chronic vitamin A overdose in man.8-10 Hence vitamin A toxicity may contribute to the abnormal calcium and skeletal metabolism that are features of renal bone disease. To study this we examined the relation between serum vitamin A concentrations and various biochemical, radiological, and histological indicators of bone disease in patients with chronic renal failure who were receiving regular haemodialysis treatment. Water-soluble vitamins are prescribed routinely in these patients to replace losses during dialysis. Many of the patients studied, however, were taking multivitamin preparations containing vitamin A, often in large quantities, and the contribution of this to the development of vitamin A toxicity was also examined. Withdrawal of vitamin A supplements in a subgroup of these patients provided an additional and more direct means of studying the effects of hypervitaminosis A on calcium and skeletal metabolism in chronic renal failure.
